Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Orestis Papasouliotis"'
Autor:
Maria Pitsiu, Özkan Yalkinoglu, Colm Farrell, Pascal Girard, Cristina Vazquez‐Mateo, Orestis Papasouliotis
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 8, Pp 1157-1169 (2023)
Abstract B cell stimulating factor (BLyS) and a proliferation‐inducing ligand (APRIL) are targets for novel treatments in patients with systemic lupus erythematosus (SLE). Atacicept is a recombinant, soluble fusion protein that blocks BLyS and APRI
Externí odkaz:
https://doaj.org/article/9efaa86ce0bd41dbb6749afefe027a5e
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 12, Pp 2888-2898 (2022)
Abstract The pharmacometric analysis of the double‐blind, randomized, phase II study (NCT02975349) investigating the safety and efficacy of evobrutinib, explored exposure–response relationships and suitable dosing regimens of evobrutinib for rela
Externí odkaz:
https://doaj.org/article/1574bc86c94149c2ace8e09bd96f649c
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 12, Pp 2899-2908 (2022)
Abstract Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown therapeutic potential in relapsing multiple sclerosis. This analysis aimed to develop pharmacokinetic (PK) and pharmacodynamic (PD; BTK occupancy [BTKO]) models of evobrutini
Externí odkaz:
https://doaj.org/article/64656ea9310f4b0f898d8fa0c197deb8
Autor:
Mahya Eslami, Daniela Willen, Orestis Papasouliotis, Sonia Schuepbach-Mallpell, Laure Willen, Olivier Donzé, Özkan Yalkinoglu, Pascal Schneider
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BAFF (B cell activation factor of the TNF family/B lymphocyte stimulator, BLyS) and APRIL (a proliferation-inducing ligand) are targeted by atacicept, a decoy receptor consisting of the extracellular domain of TACI (transmembrane activator and calciu
Externí odkaz:
https://doaj.org/article/9e52c1302a504221b6764fbf467e5860
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:655-669
Purpose Tepotinib is a highly selective, potent, mesenchymal–epithelial transition factor (MET) inhibitor, approved for the treatment of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping. Objectives of this population pharmacokineti
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Immunosuppressive drugs can alleviate debilitating symptoms of autoimmune diseases, but, by the same token, excessive immune suppression can result in an increased risk of infection. Despite the dangers of a compromised immune system, clear definitio
Autor:
Wenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg, Orestis Papasouliotis, Andreas Johne, Karin Berghoff, Kosalaram Goteti, Jennifer Dong, Pascal Girard, Karthik Venkatakrishnan, Rainer Strotmann
Publikováno v:
Cancer chemotherapy and pharmacology. 90(1)
Purpose Tepotinib is a highly selective MET inhibitor approved for treatment of non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Analyses presented herein evaluated the relationship between tepotinib exposure, and efficacy a
Autor:
Orestis Papasouliotis, Tom Leonard
Publikováno v:
A Course in Categorical Data Analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80664fa41e1784643c5e0a1292949521
https://doi.org/10.1201/9781003073109-4
https://doi.org/10.1201/9781003073109-4
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Immunosuppressive drugs can alleviate debilitating symptoms of autoimmune diseases, but, by the same token, excessive immune suppression can result in an increased risk of infection. Despite the dangers of a compromised immune system, clear definitio
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objective Atacicept is an inhibitor of the B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), and is being studied in relation to immunological disease. Currently, limited data on atacicept are available in non